Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT03172936
Previous Study | Return to List | Next Study

Study of the Safety and Efficacy of MIW815 With PDR001 in Patients With Advanced/Metastatic Solid Tumors or Lymphomas

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03172936
Recruitment Status : Completed
First Posted : June 1, 2017
Last Update Posted : February 24, 2021
Sponsor:
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The purpose of this study was to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and antitumor activity of MIW815 (ADU-S100) in combination with PDR001.

Condition or disease Intervention/treatment Phase
Solid Tumors and Lymphomas Drug: MIW815 Biological: PDR001 Phase 1

Detailed Description:

This was a Phase Ib, multi-center, open-label study to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary antitumor activity of MIW815(ADU-S100) in combination with the PD-1 checkpoint inhibitor PDR001. Two different schedules were explored in two dose escalation groups in accessible cutaneous or subcutaneous lesions. The optional dose confirmation group exploring intratumoral injection of viscerally located lesions was not opened due to the program's early termination.

Group A included patients with accessible solid tumors and lymphomas. This group received a fixed dose of PDR001 i.v. on day 1 of every 28 day cycle and intratumoral injections of MIW815 (ADU-S100) on days 1, 8 and 15 of every 28 day cycle. Group B included patients with accessible solid tumors and lymphomas. This group received a fixed dose of PDR001 i.v. on day 1 of every 28 day cycle and an intratumoral injection of MIW815 (ADU-S100) on day 1 of every 28 day cycle.

Once the dose and dose schedule had been confirmed, the plan was to open the dose expansion part of the study. However, the expansion phase of the study was not opened to enrollment due to the program's early termination.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 106 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:

The study was comprised of two treatment arms.

Group A included patients with accessible solid tumors and lymphomas. This group received a fixed dose of PDR001 intravenous on day 1 of every 28 day cycle and intratumoral injections of MIW815 (ADU-S100) on days 1, 8 and 15 of every 28 day cycle.

Group B included patients with accessible solid tumors and lymphomas. This group received a fixed dose of PDR001 intravenous on day 1 of every 28 day cycle and an intratumoral injection of MIW815 (ADU-S100) on day 1 of every 28 day cycle.

Once the maximum tolerated dose and/or recommended dose for expansion had been determined, the plan was to open the expansion part of the study. However, the dose expansion phase of the study was not opened to enrollment due to the program's early termination.

Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase Ib, Open Label, Multicenter Study of the Safety and Efficacy of MIW815 (ADU-S100) Administered by Intratumoral Injection With PDR001 to Patients With Advanced/Metastatic Solid Tumors or Lymphomas
Actual Study Start Date : September 8, 2017
Actual Primary Completion Date : December 18, 2020
Actual Study Completion Date : December 18, 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Lymphoma

Arm Intervention/treatment
Experimental: Dosing Schedule A
Patients were treated with MIW815 (ADU-S100) via intratumoral injection for 3 weeks followed by one week off in combination with a fixed intravenous dose of PDR001 given once per month
Drug: MIW815
MIW 815 (ADU-S100) is a STING agonist

Biological: PDR001
PDR001 is an anti-PD-1 antibody

Experimental: Dosing Schedule B
Patients were treated with MIW815 (ADU-S100) via intratumoral injection given once a month in combination with a fixed intravenous dose of PDR001 given once per month
Drug: MIW815
MIW 815 (ADU-S100) is a STING agonist

Biological: PDR001
PDR001 is an anti-PD-1 antibody




Primary Outcome Measures :
  1. Incidence of dose limiting toxicities (DLTs) [ Time Frame: 24 months ]
    A dose-limiting toxicity (DLT) is defined as an adverse event or abnormal laboratory value assessed as having a suspected relationship to study drug, and unrelated to disease, disease progression, inter-current illness, or concomitant medications that occurs within the first cycle of treatment with the combination of MIW815 (ADU-S100) and PDR001


Secondary Outcome Measures :
  1. AUC inf [ Time Frame: 36 months ]
    The area under the concentration-time curve extrapolated to infinity (mass*time/volume)

  2. AUC last [ Time Frame: 36 months ]
    The area under the concentration (AUC) -time curve calculated to the last quantifiable concentration point (mass* time/volume)

  3. AUC tau [ Time Frame: 36 months ]
    Area under the concentration-time curve calculated to the end of the dosing interval (tau) (mass* time/volume)

  4. Tmax [ Time Frame: 36 months ]
    The time to reach the maximum observed concentration (time)

  5. Cmax [ Time Frame: 36 months ]
    The maximum observed concentration (Cmax) following dose administration (mass/volume)

  6. Lambda_z [ Time Frame: 36 months ]
    Terminal elimination rate constant (1/time)

  7. CL/F [ Time Frame: 36 months ]
    Apparent systemic clearance of drug from the plasma (volume x time -1)

  8. T1/2 [ Time Frame: 36 months ]
    Elimination half-life, determined as 0.693/Lambda_z (time)

  9. Vz/F [ Time Frame: 36 months ]
    Apparent volume of distribution during the terminal elimination phase (volume)

  10. Best overall response (BOR) [ Time Frame: 36 months ]
    Best overall response will be summarized

  11. Overall response rate (ORR) [ Time Frame: 36 months ]
    Overall response rate will be summarized with accompanying 90% exact binomial confidence interval (CI).

  12. Progression free survival (PFS) [ Time Frame: 36 months ]
    The survival function will be estimated using the Kaplan-Meier product limit method. Median duration, with a two-sided Brookmeyer-Crowley 90% confidence interval and Kaplan-Meier estimates of survival proportions will be provided at specified time points.

  13. Disease control rate (DCR) [ Time Frame: 36 months ]
    The disease control rate is calculated as the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease

  14. Time to response (TTR) [ Time Frame: 36 months ]
    Time To Response is the time from first dose to first documented response (CR or PR). TTR will be summarized

  15. Duration of Response (DOR) [ Time Frame: 36 months ]
    Duration of response is defined as the time from the date of the first documented response (CR or PR), to the date of first documented progression, or death due to study indication. Estimates will use Kaplan-Meier method

  16. Tumor infiltrating lymphocytes (TIL) [ Time Frame: 36 months ]
    Induction of TILs in the injected lesion (local PD effect) and in a non-injected lesion (distal PD effect) will be assessed using paired tumor samples at screening and on-treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

ECOG ≤ 1 Willing to undergo tumor biopsies from injected and distal lesions

Must have two biopsy accessible lesions:

Exclusion Criteria:

Symptomatic or untreated leptomeningeal disease. Presence of symptomatic central nervous system metastases Impaired cardiac function or clinically significant cardiac disease Active autoimmune disease or a documented history of autoimmune disease, except vitiligo or resolved childhood asthma/atopy.

Active infection requiring systemic antibiotic therapy. Known history of human immunodeficiency virus infection. Active Epstein-Barr virus, hepatitis B virus or hepatitis C virus Malignant disease, other than that being treated in this study


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03172936


Locations
Layout table for location information
United States, California
The Angeles Clinic and Research Institute
Los Angeles, California, United States, 90025
United States, Illinois
Novartis Investigative Site
Chicago, Illinois, United States, 60637
United States, Texas
MD Anderson Cancer Center
Houston, Texas, United States, 77030
United States, Washington
Seattle Cancer Care Alliance
Seattle, Washington, United States, 98105
Australia, New South Wales
Novartis Investigative Site
North Sydney, New South Wales, Australia, 2060
Australia, Victoria
Novartis Investigative Site
Melbourne, Victoria, Australia, 3000
Canada, Ontario
Novartis Investigative Site
Toronto, Ontario, Canada, M5G 2M9
Germany
Novartis Investigative Site
Essen, Germany, 45147
Japan
Novartis Investigative Site
Chuo ku, Tokyo, Japan, 104 0045
Netherlands
Novartis Investigative Site
Amsterdam, Netherlands, 1066 CX
Spain
Novartis Investigative Site
Hospitalet de LLobregat, Catalunya, Spain, 08907
Switzerland
Novartis Investigative Site
Zurich, Switzerland, 8091
Sponsors and Collaborators
Novartis Pharmaceuticals
Investigators
Layout table for investigator information
Study Director: Nancy Lewis, MD Novartis
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03172936    
Other Study ID Numbers: CMIW815X2102J
2017-000707-25 ( EudraCT Number )
First Posted: June 1, 2017    Key Record Dates
Last Update Posted: February 24, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
injected lesion
distal lesion
abscopal activity
intratumoral
checkpoint inhibitor
cyclic dinucleotide
programmed cell death
Additional relevant MeSH terms:
Layout table for MeSH terms
Lymphoma
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases